Sundrug Co. Reports Strong Financial Performance for FY 2025

The latest announcement is out from Sundrug Co ( (JP:9989) ).

Sundrug Co., Ltd. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a notable increase in net sales and profits compared to the previous year. The company experienced a 6.7% rise in net sales, reaching 801,811 million yen, and a 5.6% increase in profit attributable to owners of the parent, totaling 30,750 million yen. The financial results indicate a strong performance, with improvements in operating and ordinary profits, reflecting the company’s robust market positioning and operational efficiency. The company also announced an increase in annual dividends, demonstrating its commitment to returning value to shareholders.

The most recent analyst rating on (JP:9989) stock is a Buy with a Yen4100.00 price target. To see the full list of analyst forecasts on Sundrug Co stock, see the JP:9989 Stock Forecast page.

More about Sundrug Co

Sundrug Co., Ltd. is a company listed on the Tokyo Stock Exchange, operating within the retail industry, primarily focusing on the sale of pharmaceuticals and related products.

Average Trading Volume: 412,543

Technical Sentiment Signal: Buy

Current Market Cap: Yen561.1B

For an in-depth examination of 9989 stock, go to TipRanks’ Stock Analysis page.